PMID: 490882Dec 7, 1979Paper

Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group

JAMA : the Journal of the American Medical Association


The Hypertension Detection and Follow-up Program (HDFP), in a community-based, randomized controlled trial involving 10,940 persons with high blood pressure (BP), compared the effects on five-year mortality of a systematic antihypertensive treatment program (Stepped Care [SC]) and referral to community medical therapy (Referred Care [RC]). Participants, recruited by population-based screening of 158,906 people aged 30 to 69 years in 14 communities througout the United States, were randomly assigned to SC or RC groups within each center and by entry diastolic blood pressure (DBP) (90 to 104, 105 to 114, and 115 + mm Hg). Over the five years of the study, more than two thirds of the SC participants continued to receive medication, and more than 50% achieved BP levels within the normotensive range, at or below the HDFP goal for DBP. Controls of BP was consistently better for the SC than for the RC group. Five-year mortality from all causes was 17% lower for the SC group compared to the RC group (6.4 vs 7.7 per 100, P less than .01) and 20% lower for the SC subgroup with entry DBP of 90 to 104 mm Hg compared to the corresponding RC subgroup (5.9 vs 7.4 per 100, P less than .01). These findings of the HDFP indicate that the systemat...Continue Reading

Associated Clinical Trials


Jun 5, 2003·Journal of the American Dietetic Association·UNKNOWN American Dietetic Association, UNKNOWN Dietitians of Canada
Jun 13, 1998·Psychosomatic Medicine·J D LaneC F Pieper
Oct 5, 1984·The American Journal of Medicine·R W Gifford
Aug 6, 2005·European Journal of Clinical Pharmacology·Elisabetta PoluzziNicola Montanaro
Aug 20, 1984·The American Journal of Medicine·J H Laragh
Dec 1, 1983·Controlled Clinical Trials·P L Canner
Dec 1, 1989·Controlled Clinical Trials·J Lubsen, J G Tijssen
Jun 1, 1987·Controlled Clinical Trials·B R DavisM Martin
Mar 1, 1987·Controlled Clinical Trials·R B Haynes, R Dantes
Dec 1, 1987·Controlled Clinical Trials·J D NeatonJ A Cutler
Dec 1, 1987·Controlled Clinical Trials·C E FordM J Palmer
Sep 1, 1984·Controlled Clinical Trials·R D Remington
Sep 1, 1982·Controlled Clinical Trials·W T Friedewald, J A Schoenberger
Mar 1, 1984·Controlled Clinical Trials·R V LuepkerH L Taylor
Apr 10, 2010·Journal of Women's Health·Charlotta LjungmanKarin Manhem
Oct 1, 1980·American Journal of Public Health·J C HersheyM J Reichgott
Feb 1, 1983·American Journal of Public Health·D E MoriskyC R Smith
Sep 18, 2001·Clinical Therapeutics·J M FlackUNKNOWN Study Group for Losartan in African Americans with Hypertension
Jan 1, 1982·American Journal of Public Health·D M Klos, I M Rosenstock
Oct 1, 1983·American Journal of Public Health·N DiAngelis, R V Luepker
Sep 1, 1986·American Journal of Public Health·N B ShulmanC G Miles
Jan 1, 1985·American Journal of Public Health·R N WinickoffG O Barnett
Jul 1, 1984·American Journal of Public Health·S M StahlJ Mamlin
Jun 1, 1988·American Journal of Public Health·N M Bennett, S Shea
Nov 1, 1987·American Journal of Public Health·L P HahnR J Prineas
Sep 1, 1994·American Journal of Public Health·M A Winkleby
Mar 21, 1998·Cardiology Clinics·D Perloff
Feb 1, 1997·American Journal of Public Health·R CooperR Wilks
Aug 1, 1995·Journal of General Internal Medicine·E J Pérez-StableD Feigal
Jan 19, 1980·British Medical Journal·W S Peart, W E Miall
Mar 31, 1998·BMJ : British Medical Journal·R S CooperG A Mensah
Jul 31, 1998·BMJ : British Medical Journal·C M Rembold
Aug 24, 1999·BMJ : British Medical Journal·M Stockwell
Nov 26, 1999·Journal of General Internal Medicine·P McGettiganD Henry
Jan 25, 2003·Journal of General Internal Medicine·Mari M KitahataEdward H Wagner
Jan 5, 2006·Epidemiologic Perspectives & Innovations : EP+I·Charles J CooperSara R Cooper
Apr 6, 2006·The AAPS Journal·Mehul DesaiRobert Temple

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.